Dynavax Technologies Corporation (DVAX)
|Net Income (ttm)||-5.70M|
|Day's Range||14.26 - 15.09|
|52-Week Range||3.58 - 20.40|
|Price Target||21.00 (+41.0%)|
|Est. Earnings Date||Nov 4, 2021|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.... [Read more...]
In 2020, DVAX's revenue was $46.55 million, an increase of 32.18% compared to the previous year's $35.22 million. Losses were -$75.24 million, -50.69% less than in 2019.Financial Statements
According to 4 analysts, the average rating for DVAX stock is "Strong Buy." The 12-month stock price forecast is 21.00, which is an increase of 41.03% from the latest price.
Their vaccines could be late to the party. But the stocks might still be big winners.
Valneva Completes Recruitment of Elderly Participants in Phase 3 Trial of its Inactivated COVID-19 Vaccine
Saint- Herb lain (Franc e ) , September 14 , 2021 – Valneva SE, a specialty vaccine company, today announced that it has completed recruitment of the initial cohort of elderly participants in Valneva's ...
A lost supply agreement for a partner's COVID-19 vaccine is hurting the biotech's shares today.
Dynavax Technologies Corp (NASDAQ: DVAX) is trading lower after the company announced Valneva SE (NASDAQ: VALN) received a termination notice from the United Kingdom government in relation to Valneva's ...
EMERYVILLE, Calif., Sept. 13, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that V...
Saint- Herb lain (France ) , September 13 , 2021 – Valneva SE, a specialty vaccine company, today announced that it has received a termination notice from the UK Government (“HMG”) in relation to the Su...
EMERYVILLE, Calif., Sept. 9, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ry...
EMERYVILLE, Calif., Sept. 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 224,000 shares...
One of the company's partners launched its COVID-19 vaccine in Taiwan.
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
There was some very good news on the authorization front for the company.
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation (NASDAQ: DVAX) announced the rollout of their COVID-19 vaccine, MVC-COV1901, in Taiwan. Approximately 600,000 people are antic...
Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adj...
TAIPEI, Taiwan and EMERYVILLE, Calif., Aug. 23, 2021 /PRNewswire/ -- Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production ...
Investors appeared to be rattled by the U.S. government's decision to move forward with booster doses of mRNA vaccines.
There were different reasons behind each of these COVID-19 vaccine stocks' big gains.
Merck's FDA and coronavirus vaccine news sparked momentum in biotech stocks today. Here are 4 to watch.
Is it time to add biotech stocks to your list this year? The post Hot Biotech Stocks That Deserve Your Attention In August 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
Each vaccine stock had its own separate catalyst.
Have penny stocks presented some of the biggest opportunities in the stock market? The post Are Penny Stocks Worth It?
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 150.00% and 19.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif., Aug. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported fin...
EMERYVILLE, Calif., Aug. 3, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 438,000 shares ...
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMERYVILLE, Calif. , July 21, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report seco...